Compare F5 Inc (FFIV) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Medpace Holdings Inc — how do they compare? F5 Inc trades at $402.05 (market cap $23.79B), while Medpace Holdings Inc trades at $535.39 (market cap $15.11B). The key difference: F5 Inc is the larger of the two by market cap, and F5 Inc is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| FFIV | MEDP | |
|---|---|---|
Market Cap | $23.79B | $15.11B |
Sector | Technology | Technology |
52-Week High | $431.26 | $620.59 |
52-Week Low | $223.99 | $308.88 |
Enterprise Value | $22.60B | $14.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $403.30, down 6.48% on the day, yet maintains a bullish technical trend with strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.90 surpassing the $3.46 expectation. Revenue growth is steady, reaching $3.09 billion in 2025, supported by strategic expansions into AI security, including the acquisition of SurePath AI and new platform launches.
The outlook is positive, driven by robust profitability and strategic positioning in application security. However, risks include high valuation multiples and competitive pressures. Analyst consensus is a 'Hold' with a $397 price target, slightly below the current price, indicating cautious optimism amid growth initiatives.
MEDP trades at $539.39, up 0.6% today, with a bullish technical outlook supported by moving averages and a neutral RSI. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue grew to $2.53B in 2025, and net income margins remain strong at 17.19%, though valuation ratios like P/E of 33.31 suggest premium pricing. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook: MEDP shows robust profitability and growth potential, but high valuations and legal risks warrant caution. Analyst consensus is mixed with a $497 price target below current levels, indicating limited upside. Key catalysts include Q2 2026 earnings on July 22, 2026, which could drive momentum if results exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
